Abstract: A compound comprising a ligand LA of Formula I: as well as, devices and formulations containing the compound of Formula 1 are disclosed. In the compounds, having a ligand La of Formula I: wherein R1 represents mono, or di- substitution, or no substitution; wherein R2 represents mono, di, tri, or tetra-substitution, or no substitution; wherein R is selected from hydrogen, deuterium, alkyl, cycloalkyl, and combinations thereof; wherein R1 and R2 are each independently selected from hydrogen, deuterium, alkyl, cycloalkyl, aryl, and combinations thereof; wherein any adjacent substituents of R2 are optionally joined to form a fused ring; wherein the ligand LA is coordinated to a metal M; and wherein the ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.

Abstract: Organic devices comprising an organic layer, wherein the organic layer is non-electroluminescent and comprises a cross-linked metal complex. The cross-linked metal complex may be formed by cross-linking a cross-linkable iridium complex, which comprises a set of ligands coordinated to a central iridium atom. One or more of the ligands have attached thereon, one or more polymerizable groups that are able to polymerize with other molecules to form intermolecular covalent bonds. In some cases, the organic layer may also comprise a dopant. Also provided are a method of making an organic light-emitting device, an iridium complex, and an organic-light emitting device using certain iridium complexes.

Abstract: Organic electronic devices comprising a covalently bonded organic/inorganic composite layer. The composite layer may be formed by the reaction of a metal alkoxide with a charge transport compound having one or more hydroxyl groups. Examples of metal alkoxides that can be used include vanadium alkoxides, molybdenum alkoxides, titanium alkoxides, or silicon alkoxides. This composite layer can be used for any of the various charge conducting layers in an organic electronic device, including the hole injection layer.

Abstract: Platinum compounds of Formulas I and II useful in a variety of devices, such as, for example organic-light emitting diodes (OLEDs).

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A1, A3, A5, A6, A8, R2, R7, X, Y and Z of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits and impairments, schizophrenia and other central nervous system conditions and disorders. The invention further provides compounds of Formulas II and III, and of sub-formulas of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

Abstract: Novel phosphorescent tetradentate platinum (II) compounds comprising a twisted aryl group are provided. Also provided are novel phosphorescent tetradentate platinum (II) compounds comprising an imidazo[1,2-f]phenanthridine moiety. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime.

Abstract: Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen atom. These compounds may demonstrate high photoluminescent (PL) efficiency, Gaussian emission spectra, and/or short excited state lifetimes. These materials may be especially useful as blue phosphorescent emitters.

Abstract: Disclosed is a compound having substructure F: wherein R?1 is a straight or branched chain of two or more non-fused aryl or non-fused heteroaryl groups substituted with Ra, wherein Ra is a non-fused aryl or non-fused heteroaryl, a branched or straight chain of non-fused aryl or a non-fused heteroaryl, or an alkyl substituted non-fused aryl or an alkyl substituted non-fused heteroaryl group. The compounds may be useful in phosphorescent organic light emitting devices.

Abstract: Multidentate metal complexes useful as phosphorescent emitters in display and lighting applications having the following structures:

Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Abstract: Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen atom. These compounds may demonstrate high photoluminescent (PL) efficiency, Gaussian emission spectra, and/or short excited state lifetimes. These materials may be especially useful as blue phosphorescent emitters.

Abstract: Imidazo[1,2-f]phenanthridine compounds are provided. The compounds have a twisted aryl moiety further substituted by alkyl having four or more atoms. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

Abstract: Novel phosphorescent tetradentate platinum (II) compounds comprising a twisted aryl group are provided. Also provided are novel phosphorescent tetradentate platinum (II) compounds comprising an imidazo[1,2-f]phenanthridine moiety. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime.

Abstract: Phosphorescent materials and devices with improved device manufacturing, fabrication, stability, efficiency, and/or color is disclosed.

Abstract: Imidazo[1,2-f]phenanthridine compounds are provided. The compounds have a twisted aryl moiety further substituted by alkyl having four or more atoms. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

Abstract: Novel devices comprising a layer including compounds that are capable of triplet triplet annihilation up conversation (TTA-UC) and techniques for operating the same are provided. In particular, the up-conversation layer absorbs light emitted by the OLED device and emits up-converted light with shorter wavelength in response. These devices and techniques may be used to provide improved lifetime for blue emitting devices.

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

Abstract: Novel organometallic compounds are provided, which include a 2-phenylpyridine iridium (Irppy) complex having alkyl and/or aryl substituted ligands and a heteroleptic or a homoleptic nature. These materials may be advantageously used in OLEDs to tune evaporation temperature and solubility, narrow emission, and increase device efficiency.

Abstract: Novel devices comprising a layer including compounds that are capable of triplet triplet annihilation up conversion (TTA-UC). In particular, the up-conversion layer absorbs light emitted by the OLED device and emits up-converted light with shorter wavelength in response. These devices may be used to provide improved lifetime for blue emitting devices.

Abstract: Novel devices containing organic compounds containing electron donor and acceptor characteristics and that act as emissive dopants are provided. The energy ratio obtained by dividing the T1 energy of the emissive dopant by ?EHOMO-LUMO for the same emissive dopant is at least 0.7 and the first emissive dopant has an energy difference calculated by subtracting the T1 energy of the first emissive dopant from ?EHOMO-LUMO for the first emissive dopant and the energy difference is at smaller than or equal to 1.00 eV for the novel compounds. The compounds exhibit delayed fluorescence properties when incorporated into OLED devices.